Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Chemical drugs | 1 |
Top 5 Target | Count |
---|---|
AT1R x NCC | 1 |
PPARγ x SUR1 | 1 |
Target |
Mechanism PPARγ antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Japan |
First Approval Date16 Jun 1999 |
Target |
Mechanism AT1R antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Sweden |
First Approval Date03 Nov 1998 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Dec 2024 |
Sponsor / Collaborator |
Start Date30 Nov 2024 |
Sponsor / Collaborator |
Start Date11 Oct 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Nateglinide ( PPARγ x SUR1 ) | Diabetes Mellitus, Type 2 More | Approved |
Candesartan Cilexetil/Hydrochlorothiazide ( AT1R x NCC ) | Hypertension More | Approved |
DYX116 | Diabetes Mellitus, Type 2 More | Phase 1 |